Clinical trials: Enterobacteriaceae Infections
Plague
Immunogenicity and Safety of Subunit Plague Vaccine
Plague is a potentially fatal infection in humans caused by the bacterium Yersinia pestis. Pneumonic plague is typically diagnosed in humans with high mortality.
- Trial name
- NCT02596308
- Testing
- Plague vaccine
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Bacteremia
Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins
A Phase 3, Multicenter, Randomised, Controlled, Open-Label Study to demonstrate noninferiority of temocillin (unauthorized investigational medicinal product IMP in Spain, but authorized in Belgium and UK) vs a carbapenem…
- Trial name
- ASTARTÉ (NCT04478721)
- Testing
- Temocillin, Meropenem
- Where
- 29 sites in Spain
- Volunteers
- 334 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Shigellosis
Therapeutic Induction of Endogenous Antibiotics
Shigellosis is one of the major causes of morbidity and mortality in many developing countries. The continued emergence of antibiotic resistant strains has complicated the treatment of shigellosis and has increased the cost of…
- Trial name
- NCT00800930
- Testing
- Sodium Butyrate, Saline
- Where
- 2 sites in Bangladesh
- Volunteers
- 80 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia
Real-World Study of Ceftazidime Avibactam in China
This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.
- Conditions
- Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia, Complicated Intra Abdominal Infections
- Trial name
- REACT (NCT05487586)
- Testing
- ceftazidime avibactam group
- Where
- 17 sites in China
- Volunteers
- 220 people
- Sponsor
- Pfizer
Enterobacteriaceae Infections, Fecal Microbiota Transplantation
Pilot Study Using Oral Capsule FMT to Decolonize GI CRE
Carbapenem-Resistant Enterobacteriaceae (CRE) are bacteria that have become resistant to carbapenems by producing enzymes that break down carbapenems.
- Trial name
- NCT03527056
- Testing
- Fecal Microbiota Transplantation
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Salmonella Infections
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid…
- Trial name
- NCT07286370
- Testing
- Low dose of iNTS-TCV, Full dose of iNTS-TCV, TYPHIBEV
- Where
- The Gambia
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
E. Coli Infection, Multi-antibiotic Resistance
Perinatal Transmission of MDR Bacteria
The investigators aim to conduct a prospective surveillance study of mothers and their infants born vaginally or by scheduled C-section and who are admitted to Northwestern Medicine Prentice Women's Hospital to determine the…
- Trial name
- ACQUIRE (NCT06148480)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Carbapenem Resistant Enterobacteriaceae Infection, Artificial Intelligence
A Novel Approach to Antimicrobial Resistance: Machine Learning Predictions for Carbapenem-Resistant Klebsiella in ICUs
The aim of this study to predict carbapenem resistant Klebsiella spp. earlier in our patients monitored in our Intensive Care Unit in the future, using artificial intelligence.
- Conditions
- Carbapenem Resistant Enterobacteriaceae Infection, Artificial Intelligence, Intensive Care Unit
- Trial name
- ICU (NCT05985057)
- Testing
- Artificial intelligence
- Where
- Turkey (Türkiye)
- Volunteers
- 289 people
- Sponsor
- Kocaeli University
Risk Reduction
Blood Donor CVD 5000
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries.
- Trial name
- NCT03971669
- Testing
- Vivotif Typhoid Oral Vaccine
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Salmonella Infections, Salmonella Typhimurium
Challenge Non-Typhoidal Salmonella (CHANTS) Study
This protocol describes the challenge non-typhoidal Salmonella (CHANTS) study. This is a first-in-human phase 1, double-blinded, randomised, dose-escalation human infection study, conducted in healthy volunteers aged 18 to 50…
- Conditions
- Salmonella Infections, Salmonella Typhimurium, Non-typhoidal Salmonella (NTS), Invasive Non-Typhoidal Salmonella Disease
- Trial name
- CHANTS (NCT05870150)
- Testing
- Salmonella Typhimurium
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Enterobacteriaceae Infection
Qnr Genes in Enterobacteriaceae
Enterobacteriaceae are bacteria of the gastrointestinal tract which are also the most frequently involved in bacterial infections, especially urinary tract infections.
- Trial name
- NCT02834910
- Testing
- collection of bacterial sample
- Where
- France
- Volunteers
- 133 people
- Sponsor
- CHU de Reims
Resistance Bacterial, Enterobacteriaceae Infections
Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities
The continuing spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) is among the most important problems in antimicrobial resistance.
- Trial name
- MODERN (NCT03477084)
- Testing
- ESBL-producing enterobacteriaceae carriage
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Septic Shock
Pentaglobin in CRE and PA Neutropenic Infections
To demonstrate that the early addition of Pentaglobin to the best available antimicrobial therapy is able to reduce mortality and improve survival in neutropenic febrile acute leukemia or allo- Hematopoietic stem cell…
- Trial name
- PENTALLO (NCT03494959)
- Testing
- Pentaglobin
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Typhoid
Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine
This is a randomized, observer-blinded Phase 2 study in healthy infants and toddlers 6-23 months of age at the time of the first vaccine dose.
- Trial name
- NCT03527355
- Testing
- Vi-DT, FluQuadri™, 0.9% sodium chloride isotonic solution
- Where
- Philippines
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Klebsiella Infections
Prognosis of Klebsiella ESBL Sepsis: Role of 2-HYDRoxy-myristate in Endotoxin Structure
Infections constitute a multiple and heterogeneous set of pathologies, and the first cause of mortality worldwide. Among them, sepsis is a more recent nosological entity, including the most severe forms of acute infectious…
- Trial name
- PoKES2_HYDRES (NCT05193045)
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Typhoid Fever
Safety and Immunogenicity of Typhax, a Typhoid Vaccine
This was a randomized, double-blind, ascending dose study conducted at a single clinical research center.
- Trial name
- NCT03926455
- Testing
- Typhax (investigational typhoid fever candidate vaccine), Active Comparator Typhim Vi
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Matrivax Research and Development Corporation
Carbapenem-Resistant Enterobacteriaceae Infection
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against…
- Trial name
- NCT05850871
- Testing
- CAZ/AVI plus Aztreonam, Conventional treatment
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Qianfoshan Hospital
Shigellosis
Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a
In this proof of concept challenge study, the bioconjugate candidate vaccine Flexyn2a will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella…
- Trial name
- NCT02646371
- Testing
- Flexyn2a
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Infection Due to Resistant Organism
FMT for MDRO Colonization After Infection in Renal Transplant Recipients
Transplant patients are at increased risk of colonization and infection with Multidrug Resistant Organisms (MDROs) due to medications that modify their immune systems, increased healthcare and antibiotic exposure, and surgical…
- Trial name
- PREMIX (NCT02922816)
- Testing
- Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Influenza, Hepatitis A
Effects of Aging on Primary and Secondary Vaccine Responses
The purpose of this study is to use an existing, unique clinical cohort: the longitudinal cohort of younger (21-40 years) and elderly (>65 years) subjects whose yearly influenza vaccine responses have been studied extensively…
- Conditions
- Influenza, Hepatitis A, Typhoid, Healthy Adults
- Trial name
- SLVP033 (NCT03312699)
- Testing
- Fluzone® quadrivalent, Fluzone High Dose, Fluad
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Stanford University